This program project grant application seeks support for clinical research projects dealing with bone marrow transplantation for hematologic malignancies. The clinical section focuses on marrow transplantation as a treatment for acute myelogenous and lymphocytic leukemias, acute malignant myelofibrosis and the accelerated phase of chronic granulocytic leukemia. In a study on the molcular aspects of hemoglobin F, features of fetal erythropoiesis after marrow grafting will be investigated. The assessment of antibody formation against transfused platelets and granulocytes, the validity of newly described in vitro compatibility tests and the response to platelet transfusions and granulocyte transfusions will be evaluated. Immunological reconstitution and its relationship to interstitial pneumonia in recipients of allogeneic marrow grafts will be studied using immunologic markers. The biologic significance of cytomegalovirus infection after marrow grafting will be studied by sequential virus cytomegalovirus polypeptides and glycoproteins. Molecular clonging of purified cytomegalovirus polypeptides will be attempted as a means of producing highly purified response to purified isolation, by clinical detection of viral proteins, and by determination of the immune antigen. Another project addresses the problem of prevention and treatment of graft versus host disease by the use of monoclonal antibodies in an animal system. FInally a murine system will be studied as a model for autologens marrow transplantation as a therapy of acute leukemia after in vitro manipulation of the marrow innoculum with drugs, monoclonal antibodies or anti-lymphocyte sera.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA030206-04A1
Application #
3093375
Study Section
Clinical Cancer Program Project Review Committee (CCP)
Project Start
1981-07-01
Project End
1988-01-31
Budget Start
1985-05-01
Budget End
1986-01-31
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications